Back to search

Boston University

Small molecule modulation of immune-mediated disorders

Abstract

dc:description.abstract

The immune system is a complex network of cells, tissues, and molecules, that serves as the frontline defense against pathogens and foreign antigens. Cytokines are key regulators for its function, orchestrating the complex interplay between immune cells. Disruptions in cytokine signaling can precipitate immune dysregulation, tipping the delicate balance between protective immunity and pathological inflammation. Cytokine imbalances, characterized by overexpression or dysregulated signaling, result in chronic inflammation, autoimmune disorders, and cancer. Simultaneously, dysregulated immune activation pathways, including those involving antigen-presenting cells and T-cell responses, contribute to the breakdown of immune tolerance and the onset of autoimmunity.The current suite of therapeutics for targeting soluble proinflammatory cytokines and receptor units consists of monoclonal antibodies which are often limited by an intravenous route of administration, low tissue penetration, off-target effects, non-specific elimination, immunogenicity, and high cost of production. Small molecule therapeutics have advantages such as oral administration and increased tissue penetration but pose challenges in discovery and development. To address this, rational drug design approaches utilizing high throughput screening and structure-based fragment identification can be employed. Here, we describe potent new inhibitors for the cytokine IL-4 from structure-activity studies and we profiled a panel of 33 disease-relevant human cytokines to identify small-molecule ligands and inhibitors to survey their tractability for small-molecule modulation. Using a small-molecule microarray-based approach the binding preferences of each cytokine were compared against a collection of 65,000 drug and lead-like compounds From this screen, 841 key chemical chemotypes were identified that define structural motifs that bias for binding to specific cytokines. These chemotypes were further validated in thermal shift assays, resulting in 281 cytokine binders. Six cytokines were prioritized and established that novel, first-in-class inhibitors can be identified from these binders with potencies ranging from single-digit to double-digit micromolar in reporter and functional cellular assays. For the first time, these studies show that cytokines are broadly amenable to small-molecule binding and inhibition with key insights into the chemical structures that can enable the inhibition of specific cytokines. Additionally, a structure-based fragment design was implemented targeting HLA-DQ8 for innovative therapies in type 1 diabetes mellitus (T1DM) to counter immune activation. Genetic predispositions result in autoreactive T cells evading negative selection, leading to the production of autoantibodies against insulin B (9:23) peptide, marking the presymptomatic stage. This stage often remains undiagnosed for months to years, varying among patients. It is succeeded by the symptomatic stage, characterized by a two-thirds reduction in β cell mass due to pancreatic infiltration. Previous attempts to prevent T1DM onset have been hindered by unspecificity and immunosuppression. Recently, the FDA approved Anti-CD3, a monoclonal antibody, to delay symptomatic stage T1DM onset in adults and pediatric patients aged 8 years and older. Diabetic HLA-DQ8 recognizes insulin B (9:23) peptide as a foreign antigen, triggering T cell receptor activation, clonal expansion, pancreatic infiltration, and eventual β cell death. The binding of diabetic HLA-DQ8 and insulin B (9:23) peptide involves three key interactions at the P1, P4, and P9 pockets. Leveraging structural insights into HLA-DQ8 and insulin B (9:23) peptide interactions, our structure-based fragment design approach identified 16 binder fragments, offering the potential for precise immunomodulation in T1DM treatment. In summary, novel potent small molecule inhibitors targeting dysregulated cytokine signaling were discovered and evaluated which will further advance drug discovery and development efforts. Furthermore, structure-based fragment design targeting HLA-DQ8 mediated immunoactivation in T1DM lays a critical foundation for the future development of HLA-DQ8-specific fragments. This approach offers a potential avenue for restoring balance within the immune system and represents a significant step forward in the quest for effective therapeutics against immune-mediated disorders.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Molecular Biology, Cell Biology & Biochemistry
Grantor
Boston University
Year dc:date.issued
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Raavi
Advisor dc:contributor.advisor
  • Vegas, Arturo J.
ORCID dc:identifier.orcid

Subjects

dc:subject × 5

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/51388

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Raavi. Small molecule modulation of immune-mediated disorders. doctoral thesis, Boston University, 2024. https://hdl.handle.net/2144/51388